Progress & Timeline
Our progress to date
Key milestones across SofiaSante's obesity therapeutic, delivery, half-life extension and oncology programs.
CSIRO research partnership commenced
SofiaSante commenced a research partnership with CSIRO under the CSIRO Kick-Start Program to assess the feasibility of its transdermal drug-delivery platform.
CSIRO scoping study completed
CSIRO completed a scoping study and concluded that SofiaSante's transdermal delivery approach is technically viable and suitable for further experimental proof-of-concept development, subject to addressing key translational requirements.
Research Partnership Agreement entered into with a University in the People's Republic of China
SofiaSante entered into a Research Partnership Agreement with a University in the People's Republic of China for in-silico design and access to a supercomputer for the in-silico design.
Computational design and candidate generation
The lead obesity program progressed through large-scale candidate generation, computational enrichment, structural evaluation, and molecular-dynamics-informed prioritisation to support candidate shortlisting.
Candidate shortlisting and validation preparation
SofiaSante is preparing to move selected lead candidates into synthesis and first wet-lab validation.
First synthesis and in vitro validation
Selected candidates are intended to progress into synthesis, receptor pharmacology, and early biological validation.
Half-life extension integration
SofiaSante will evaluate half-life extension approaches intended to improve duration of action, receptor engagement pattern, and long-term pharmacodynamic performance.
Delivery-platform proof of concept
SofiaSante plans to translate CSIRO's feasibility findings into focused proof-of-concept studies for controlled transdermal delivery.
Oncology adjunct concept validation
SofiaSante is exploring adjunct conjugates designed to improve the tumour microenvironment and reduce treatment-limiting chemotherapy side effects.